Anabolic androgenic steroids impact on cardiovascular risk and cardiovascular events. The literature review
DOI:
https://doi.org/10.12775/QS.2026.53.70123Keywords
anabolic androgenic steroids, cardiovascular complications, Cardiovascular disease, drug abuse, Vascular Calcification, Atherosclerosis, risk of venous thromboembolism, Hypertension, cardiac hypertrophy, arrythmias, Myocardial infarction, Sudden cardiac death, gymAbstract
Background: Anabolic-androgenic steroids are used as a form of doping. Scientific research shows the association of AAS use with multidirectional effects on the cardiovascular system.
Aim: To collect overall information on the effects of AAS on the cardiovascular system based on current scientific studies.
Material and methods: The literature available in PubMed and Google Scholar databases was reviewed using the keywords.
Results: The results of scientific studies have confirmed the effects of AAS on vascular calcification and the development of atherosclerosis. Studies suggest an increased risk of thromboembolic incidents (lack of general consensus). AAS use is associated with the development of hypertension and left ventricular hypertrophy. Their consequences include impaired cardiac systolic and diastolic function, arrhythmias and susceptibility to ischemia. The use of AAS carries the risk of arrhythmias of ventricular and supraventricular origin. AAS increase the risk of myocardial infarction both in the mechanism of coronary artery stenosis and without significant stenosis.
Conclusions: AAS use is associated with increased cardiovascular risk and cardiovascular events. A collective knowledge of the effects of AAS abuse may be useful in the diagnostic and therapeutic process, as well as to develop methods for primary prevention. Some of the effects of AAS use require further research.
References
1. Mutschler „Farmakologia i Toksykologia” IV wydanie s.409-410.
2. Marianna Zając, Ewaryst Pawełczyk, Anna Jelińska: Chemia leków dla studentów farmacji i farmaceutów. Wyd. II. Poznań: Akademia Medyczna w Poznaniu, 2006, s.355-356.
3. Liu JD, Wu YQ. Anabolic-androgenic steroids and cardiovascular risk. Chin Med J (Engl). 2019 Sep 20;132(18):2229-2236. doi: 10.1097/CM9.0000000000000407. PMID: 31478927; PMCID: PMC6797160.
4. Pope HJ, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014; 35:341–375. doi: 10.1210/er.2013-1058.
5. Armstrong JM, Avant RA, Charchenko CM, Westerman ME, Ziegelmann MJ, Miest TS, et al. Impact of anabolic androgenic steroids on sexual function. Transl Androl Urol 2018; 7:483–489. doi: 10.21037/tau.2018.04.23.
6. Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol 2015; 173:R47–R58. doi: 10.1530/EJE-15-0080.
7. Medras M, Brona A, Jozkow P. The central effects of androgenic-anabolic steroid use. J Addict Med 2018; 12:184–192. doi: 10.1097/ADM.0000000000000395.
8. Skarberg K, Nyberg F, Engstrom I. The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. Subst Abuse Treat Prev Policy 2008; 3:24.doi: 10.1186/1747-597X-3-24.
9. D’Andrea A, Limongelli G, Morello A, Mattera IA, Russo MG, Bossone E, et al. Anabolic-androgenic steroids and athlete's heart: when big is not beautiful....!. Int J Cardiol 2016; 203:486–488. doi: 10.1016/j.ijcard.2015.10.186.
10. Graham MR, Davies B, Grace FM, Kicman A, Baker JS. Anabolic steroid use: patterns of use and detection of doping. Sports Med. 2008;38(6):505-25.
11. Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014 May;24(5):383-98.
12. Givens ML, Deuster PA. Androgens and Androgen Derivatives: Science, Myths, and Theories: Explored From a Special Operations Perspective. J Spec Oper Med. 2015 Fall;15(3):98-104. doi: 10.55460/8M1J-GJFL. PMID: 26360363
13. Zhu D, Hadoke PW, Wu J, Vesey AT, Lerman DA, Dweck MR, Newby DE, Smith LB, MacRae VE. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci Rep. 2016 Apr 20;6:24807. doi: 10.1038/srep24807. PMID: 27095121; PMCID: PMC4837411.
14. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int. 2013 Oct;93(4):365-73. doi: 10.1007/s00223-013-9712-z. Epub 2013 Mar 1. PMID: 23456027; PMCID: PMC3714357.
15. Buhl LF, Christensen LL, Hjortebjerg R, et al. Illicit Anabolic Steroid Use and Cardiovascular Status in Men and Women. JAMA Netw Open. 2025;8(8):e2526636. doi:10.1001/jamanetworkopen.2025.26636
16. Santora LJ, Marin J, Vangrow J, Minegar C, Robinson M, Mora J, Friede G. Coronary calcification in body builders using anabolic steroids. Prev Cardiol. 2006 Fall;9(4):198-201. doi: 10.1111/j.1559-4564.2006.05210.x. PMID: 17085981.
17. L. McRobb, D. J. Handelsman, A. K. Heather, Androgen-Induced Progression of Arterial Calcification in Apolipoprotein E-Null Mice Is Uncoupled from Plaque Growth and Lipid Levels, Endocrinology, Volume 150, Issue 2, 1 February 2009, Pages 841–848, https://doi.org/10.1210/en.2008-0760
18. Baldo-Enzi G, Giada F, Zuliani G, Baroni L, Vitale E, Enzi G, Magnanini P, Fellin R. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism. 1990;39:203–208. doi: 10.1016/0026-0495(90)90076-o
19. Fröhlich J, Kullmer T, Urhausen A, Bergmann R, Kindermann W. Lipid profile of body builders with and without self-administration of anabolic steroids. Eur J Appl Physiol. 1989;59:98–103. doi: 10.1007/BF02396586.
20. Lane H, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006;36:483–488. doi: 10.1111/j.1365-2362.2006.01667.x
21. Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, Van’t Laar A, Thien T. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur bodybuilders. Int J Sports Med. 1988;9:19–23. doi: 10.1055/s-2007-1024972.
22. Anabolic androgenic steroids may be associated with early coronary artery disease. Cardiovasc J Afr. 2018 Mar-Apr;29(2):105. PMCID: PMC6008908.
23. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, Pope HG Jr. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017 May 23;135(21):1991-2002. doi: 10.1161/CIRCULATIONAHA.116.026945. PMID: 28533317; PMCID: PMC5614517.
24. Chang S, Rasmussen JJ, Frandsen MN, Schou M, Johansen ML, Faber J, Münster AB, Sidelmann JJ, Kistorp C. Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers. Thromb Haemost. 2018 Apr;118(4):647-653. doi: 10.1055/s-0038-1636540. Epub 2018 Apr 4. PMID: 29618151.
25. Camilleri E, Smit DL, van Rein N, Le Cessie S, de Hon O, den Heijer M, Lisman T, Cannegieter SC, de Ronde W. Coagulation profiles during and after anabolic androgenic steroid use: data from the HAARLEM study. Res Pract Thromb Haemost. 2023 Oct 10;7(7):102215. doi: 10.1016/j.rpth.2023.102215. PMID: 38077826; PMCID: PMC10704519.
26. Fyksen TS, Seljeflot I, Vanberg P, Atar D, Halvorsen S. Platelet activity, coagulation, and fibrinolysis in long-term users of anabolic-androgenic steroids compared to strength-trained athletes. Thromb Res. 2024 Jun;238:60-66. doi: 10.1016/j.thromres.2024.04.027. Epub 2024 Apr 24. PMID: 38676967.
27. Rasmussen JJ, Schou M, Madsen PL, Selmer C, Johansen ML, Hovind P, Ulriksen PS, Faber J, Gustafsson F, Kistorp C. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J Hypertens. 2018 Feb;36(2):277-285. doi: 10.1097/HJH.0000000000001546. PMID: 28863033.
28. Davani-Davari, D., Karimzadeh, I. & Khalili, H. The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review. BMC Nephrol 20, 198 (2019). https://doi.org/10.1186/s12882-019-1384-0
29. R Falconi, M Campos, L Mello, C Garcia, J Giffoni, R R T Castro, Anabolic steroid abuse accelerates arterial ageing, European Journal of Preventive Cardiology, Volume 32, Issue Supplement_1, May 2025, zwaf236.402, https://doi.org/10.1093/eurjpc/zwaf236.402
30. Gheshlaghi F, Piri-Ardakani MR, Masoumi GR, Behjati M, Paydar P. Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes. J Res Med Sci. 2015 Feb;20(2):165-8. PMID: 25983770; PMCID: PMC4400712.
31. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004 May;90(5):496-501. doi: 10.1136/hrt.2003.015719. PMID: 15084541; PMCID: PMC1768225.
32. Di Bello V, Giorgi D, Bianchi M, Bertini A, Caputo MT, Valenti G, Furioso O, Alessandri L, Paterni M, Giusti C. Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc. 1999 Apr;31(4):514-21. doi: 10.1097/00005768-199904000-00004. PMID: 10211845.
33. Karila TA, Karjalainen JE, Mäntysaari MJ, Viitasalo MT, Seppälä TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med. 2003 Jul;24(5):337-43. doi: 10.1055/s-2003-40702. PMID: 12868044.
34. Palatini P, Giada F, Garavelli G, Sinisi F, Mario L, Michieletto M, Baldo-Enzi G. Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol. 1996 Dec;36(12):1132-40. doi: 10.1002/j.1552-4604.1996.tb04167.x. PMID: 9013370.
35. Far HR, Ågren G, Thiblin I. Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovasc Pathol. 2012 Jul-Aug;21(4):312-6. doi: 10.1016/j.carpath.2011.10.002. Epub 2011 Nov 21. PMID: 22104006.
36. D'Andrea A, Caso P, Salerno G, Scarafile R, De Corato G, Mita C, Di Salvo G, Severino S, Cuomo S, Liccardo B, Esposito N, Calabrò R. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med. 2007 Mar;41(3):149-55. doi: 10.1136/bjsm.2006.030171. Epub 2006 Dec 18. PMID: 17178777; PMCID: PMC2465218.
37. Luijkx T, Velthuis BK, Backx FJ, Buckens CF, Prakken NH, Rienks R, Mali WP, Cramer MJ. Anabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. Int J Cardiol. 2013 Aug 10;167(3):664-8. doi: 10.1016/j.ijcard.2012.03.072. Epub 2012 Mar 28. PMID: 22459398.
38. Chrostowski, K.; Kwiatkowska, D.; Pokrywka, A.; Stańczyk, D.; Wójcikowska-Wójcik, B.; Grucza, R. Renin-Angiotensin-Aldosterone System in Bodybuilders Using Supraphysiological Doses of Anabolic-Androgenic Steroids. Biol. Sport. 2011, 28, 11–17.
39. Delles C, Schmidt BM, Müller HJ, Oehmer S, Klingbeil AU, Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol. 2003 Feb 1;91(3):297-301. doi: 10.1016/s0002-9149(02)03158-2. PMID: 12565086.
40. Torrisi, M.; Pennisi, G.; Russo, I.; Amico, F.; Esposito, M.; Liberto, A.; Cocimano, G.; Salerno, M.; Li Rosi, G.; Di Nunno, N.; et al. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina 2020, 56, 587. https://doi.org/10.3390/medicina56110587.
41. Seara FAC, Barbosa RAQ, de Oliveira DF, Gran da Silva DLS, Carvalho AB, Freitas Ferreira AC, Matheus Nascimento JH, Olivares EL. Administration of anabolic steroid during adolescence induces long-term cardiac hypertrophy and increases susceptibility to ischemia/reperfusion injury in adult Wistar rats. J Steroid Biochem Mol Biol. 2017 Jul;171:34-42. doi: 10.1016/j.jsbmb.2017.01.012. Epub 2017 Feb 6. PMID: 28179209.
42. Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology. 1997 Mar-Apr;88(2):218-20. doi: 10.1159/000177333. PMID: 9096926.
43. Han HC, Farouque O, Hare DL. Steroid-induced cardiomyopathy. Med J Aust. 2015 Sep 7;203(5):226-7.e1. doi: 10.5694/mja14.01491. PMID: 26852057.
44. Skorupska, K., Skorupski, W., Gąsiorowski, M., Lesiak, M., Straburzyńska-Migaj, E., & Kałużna-Oleksy, M. (2022). Disastrous effects of anabolic steroids abuse: a peculiar case of heart failure and toxic hepatitis in a young bodybuilder. Polskie Archiwum Medycyny Wewne̦trznej. https://doi.org/10.20452/pamw.16355
45. Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med. 2017 Feb 22;9(1):20. doi: 10.1186/s13073-017-0410-8. PMID: 28228157; PMCID: PMC5322656.
46. Camara Puppin, C. G., Andrade Moraes, F. D. S., Rocha Gomes, L. R., do Nascimento, A. M., de Lima, E. M., Brasil, G. A., Bissoli, N. S., Lenz, D., Endringer, D. C. & de Andrade, T. U. (2019). Anabolic androgenic steroid users: a tilt test study with young adult men. Archives of Medical Science – Civilization Diseases, 4(1), 75–83. https://doi.org/10.5114/amscd.2019.86992
47. Barbosa Neto O, da Mota GR, De Sordi CC, Resende EAMR, Resende LAPR, Vieira da Silva MA, Marocolo M, Côrtes RS, de Oliveira LF, Dias da Silva VJ. Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities. Clin Auton Res. 2018 Apr;28(2):231-244. doi: 10.1007/s10286-017-0470-2. Epub 2017 Oct 10. PMID: 29019018.
48. Maior AS, Carvalho AR, Marques-Neto SR, Menezes P, Soares PP, Nascimento JH. Cardiac autonomic dysfunction in anabolic steroid users. Scand J Med Sci Sports. 2013 Oct;23(5):548-55. doi: 10.1111/j.1600-0838.2011.01436.x. Epub 2012 Jan 18. PMID: 22257181.
49. Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. Handb Exp Pharmacol. 2010;(195):411-57. doi: 10.1007/978-3-540-79088-4_18. PMID: 20020375.
50. Akçakoyun M, Alizade E, Gündoğdu R, Bulut M, Tabakcı MM, Açar G, Avcı A, Simşek Z, Fidan S, Demir S, Kargın R, Emiroğlu MY. Long-term anabolic androgenic steroid use is associated with increased atrial electromechanical delay in male bodybuilders. Biomed Res Int. 2014;2014:451520. doi: 10.1155/2014/451520. Epub 2014 May 4. PMID: 24883314; PMCID: PMC4026920.
51. Baytugan NZ, Kandemir HÇ. The effect of anabolic androgenic steroids on heart rate recovery index and electrocardiographic parameters in male bodybuilders. J Electrocardiol. 2024 May-Jun;84:95-99. doi: 10.1016/j.jelectrocard.2024.03.015. Epub 2024 Apr 1. PMID: 38579637.
52. Ghorbani Baravati H, Joukar S, Fathpour H, Kordestani Z. Nandrolone Plus Moderate Exercise Increases the Susceptibility to Lethal Arrhythmias. Res Cardiovasc Med. 2015 May 23;4(2):e26233. doi: 10.5812/cardiovascmed.26233v2. PMID: 26396972; PMCID: PMC4576214.
53. Medei E, Marocolo M, Rodrigues Dde C, Arantes PC, Takiya CM, Silva J, Rondinelli E, Goldenberg RC, de Carvalho AC, Nascimento JH. Chronic treatment with anabolic steroids induces ventricular repolarization disturbances: cellular, ionic and molecular mechanism. J Mol Cell Cardiol. 2010 Aug;49(2):165-75. doi: 10.1016/j.yjmcc.2010.04.014. Epub 2010 May 10. PMID: 20462507.
54. Rajan D, Zörner CR, Hansen ML, Tfelt-Hansen J. Arytmie i nagła śmierć: co nowego w kardiomiopatii przerostowej? Card Fail Rev. 2025 1 kwietnia;11:e08. doi: 10.15420/cfr.2024.38. PMID: 40242137; PMCID: PMC12001045.
55. Bulut Y, Rasmussen JJ, Brandt-Jacobsen N, et al. Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use. JAMA Netw Open. 2024;7(12):e2451013. doi:10.1001/jamanetworkopen.2024.51013
56. Seara FAC, Olivares EL, Nascimento JHM. Anabolic steroid excess and myocardial infarction: From ischemia to reperfusion injury. Steroids. 2020 Sep;161:108660. doi: 10.1016/j.steroids.2020.108660. Epub 2020 May 31. PMID: 32492466.
57. M. Ferrer, A. Encabo, J. Marin, G. Balfagon Chronic treatment with anabolic steroid, nandrolone, inhibits vasodilatory responses in rabbit aorta
58. Schrör K, Morinelli TA, Masuda A, Matsuda K, Mathur RS, Halushka PV. Testosterone treatment enhances thromboxane A2 mimetic induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest. 1994 Feb;24 Suppl 1:50-2. doi: 10.1111/j.1365-2362.1994.tb02428.x. PMID: 8013532.
59. Sonmez E, Turkdogan KA, Yilmaz C, Kucukbuzcu S, Ozkan A, Sogutt O. Chronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk J Emerg Med. 2016 Mar 10;16(1):35-7. doi: 10.1016/j.tjem.2014.11.001. PMID: 27239638; PMCID: PMC4882200.
60. Nakao J, Change WC, Murota SI, Orimo H. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis. 1981 May;39(2):203-9. doi: 10.1016/0021-9150(81)90070-8. PMID: 7018504.
61. Abdelsamie, A, Abdelhadi, H. Impact of Anabolic-Androgenic Steroids on Coronary Artery Disease: Insights From Optical Coherence Tomography. J Am Coll Cardiol Case Rep. 2025 Aug, 30 (24) .
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Eryk Ubysz, Patrycja Kwitowska, Łukasz Muraszewski, Emilia Muraszewska, Małgorzata Pyjecka, Agata Król, Edyta Lewandowska, Cezary Łuczyński, Maciej Paczkowski, Mariusz Wręczycki
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 61
Number of citations: 0
